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Immunopathology and Infectious Disease
Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune
Encephalomyelitis
Wassim Elyaman,* Pia Kivisäkk,* Jay Reddy,* Tanuja Chitnis,* Khadir Raddassi,* Jaime Imitola,* Elizabeth Bradshaw,* Vijay K. Kuchroo,* Hideo Yagita,‡ Mohamed H. Sayegh,† and Samia J. Khoury*
From the Center for Neurologic Diseases,* Brigham and Women’s Hospital, and Transplantation Center,† Brigham and Women’s Hospital and
Children’s Hospital, Harvard Medical School, Boston, Massachusetts; and Department of Immunology,‡ Juntendo University School of Medicine, Tokyo, Japan

The persistence of human autoimmune diseases is thought to be mediated predominantly by memory T cells. We investigated the phenotype and migration of memory versus effector T cells in vivo in experimental autoimmune encephalomyelitis
(EAE). We found that memory CD4+ T cells up-regulated the activation marker CD44 as well as CXCR3 and ICOS, proliferated more and produced more interferon-γ and less interleukin-17 compared to effector T cells. Moreover, adoptive transfer
of memory T cells into T cell receptor (TCR)αβ-/- recipients induced more severe disease than did effector CD4+ T cells with
marked central nervous system inflammation and axonal damage. The uniqueness of disease mediated by memory T cells
was confirmed by the differential susceptibility to immunomodulatory therapies in vivo. CD28-B7 T cell costimulatory signal
blockade by CTLA4Ig suppressed effector cell-mediated EAE but had minimal effects on disease induced by memory cells.
In contrast, ICOS-B7h blockade exacerbated effector T cell-induced EAE but protected from disease induced by memory T
cells. However, blockade of the OX40 (CD134) costimulatory pathway ameliorated disease mediated by both memory and
effector T cells. Our data extend the understanding of the pathogenicity of autoreactive memory T cells and have important
implications for the development of novel therapies for human autoimmune diseases.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) white
matter in which T cells and their mediators trigger injury of
axons and their myelin sheaths through a complex sequence
of events.1-5 T cell-mediated inflammation is driven by an autoimmune process, which in turn can trigger a degenerative
phase that is independent of immune responses.2 Although
the nature of the autoreactive T cells in MS patients is not yet
fully understood, there is evidence that these T cells belong
to the long-lived memory T cell pool.6-9
Memory CD4+ T cells express a pattern of surface markers
different from that of naïve or effector cells, and their responses to immune stimuli are functionally different.10 Murine memory cells are high in CD44 and low in the expression
of activation markers such as CD25. Memory cells can persist
in the absence of antigenic stimulation as nondividing cells.10
Re-encounter with the same antigen can expand the population to a stable, higher level and generate a separate population of CD44 high effector T cells.11 Two subsets of memory
T cells, called central-memory (TCM) and effector-memory
(TEM) T cells, are described based on their anatomical location, expression of cell surface markers, and effector funcSupported by research grants from the National Institutes of Health
(R01AI067472, AI058680, and AI043496 to S.J.K.; R01AI037691 to M.H.S.) and
the National Multiple Sclerosis Society (RG3666, RG2988, and RG3504 to S.J.K.).
W.E. is a recipient of a National Research Service Award fellowship from the
National Institute of Neurological Disorders and Stroke (F32NS059205-01A1).
P.K. is a recipient of an advanced fellowship from the National Multiple Sclerosis Society.
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Accepted for publication May 13, 2008.
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Address reprint requests to Samia J. Khoury, M.D., Center for Neurologic
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rics.bwh.harvard.edu.

tions.12 TCM cells express molecules such as CD62L and CCR7,
which allow efficient homing to lymph nodes, whereas TEM
cells lack expression of these lymph node homing receptors
and are located in nonlymphoid tissues. However, both T
cell subsets are present in the blood and spleen. Some studies have also shown that TEM cells acquire effector functions,
such as cytokine production and killing, more rapidly than
do TCM.13-15
The induction of immunological tolerance is an important
clinical goal in autoimmunity. Strategies designed specifically to suppress the function of chronically activated memory T cells without impairing the function of naïve T cells
therefore have value in the treatment of autoimmune diseases. Two signals are required for T cell activation: antigen
recognition and costimulatory signals. Several costimulatory
pathways important in the activation of T cells have been
identified.16,17 Costimulatory molecules may deliver either a
stimulatory (positive) or inhibitory (negative) signal for T cell
activation.18 The delicate balance between positive and negative regulatory signals can determine the outcome of a specific immune response. It has been suggested that memory
T cells are less dependent on positive costimulatory signals
than naïve cells for activation on antigen encounter11,19,20 or
may require different costimulatory signals. In humans, ex
vivo activated myelin-reactive T cells from multiple sclerosis
patients are independent of CD28-B7 costimulation.7,9 However, in vivo murine studies showed that activation of effector-memory CD4+ T cells may be abrogated by blocking the
CD28-B7 pathway.21 Furthermore, it was recently shown that
memory CD8+ T cells require CD28 costimulation to generate
maximal secondary responses against pathogens.22
Experimental autoimmune encephalomyelitis (EAE) is an
inflammatory disease of the central nervous system that
mimics certain aspects of MS. Although no animal model can
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replicate MS completely, this model is valuable in addressing
specific questions of pathogenesis and potential therapies.
However, most studies have focused on targeting prevention
of disease or therapy of early disease that may not be fully
applicable to human disease, which is probably perpetuated
by memory T cells. The understanding of CD4+ memory T
cell function and regulation comes mostly from in vitro studies or limited in vivo studies, but there is no disease model
mediated purely by memory T cells. Here we establish a new
EAE disease model mediated by antigen-specific memory
CD4+ T cells generated in vivo. Our data show that memory
CD4+ T cells induce more severe disease than effector CD4+
T cells caused by a preferential differentiation of memory T
cells into the Th1 phenotype and a differential expression of
chemokine receptors and costimulatory molecules leading
to severe CNS inflammation. Furthermore, our data using
costimulatory blocking agents show the requirement of the
Inducible costimulator-B7h and OX40 pathways in disease
mediated by memory CD4+ T cells. Our findings have implications for the treatment of human autoimmune diseases
and translating novel tolerance strategies to the clinic.
Materials and Methods
Mice and EAE Induction with Myelin Oligodendrocytes Glycoprotein (MOG)
Female wild-type (WT) and T cell receptor (TCR)αβ-/C57BL/6 mice were purchased from The Jackson Laboratory
(Bar Harbor, Maine). MOG-TCR mice (2D2) were provided by
V. Kuchroo (Brigham and Women’s Hospital, Boston, Massachusetts). All animal experiments were performed with the
approval of the Harvard Medical Area Standing Committee
on Animals. EAE was induced in C57BL/6 WT and TCRαβ-/mice as described previously.23 MOG peptide 35-55 (M-E-VG-W-Y-R-S-P-F-S-R-O-V-H-L-Y-R-N-G-K), corresponding to
the mouse sequence, was synthesized by Quality Controlled
Biochemicals Inc., a division of Biosource International (Hopkinton, Massachusetts) and purified to greater than 99% by
high-performance liquid chromatography. C57BL/6 WT and
TCRαβ-/- mice were immunized subcutaneously in the flank
with 100 μg of myelin oligodendrocyte glycoprotein peptide
of amino acids 35-55 (MOG35-55) peptide in 0.1 ml of PBS
and 0.1 ml of complete Freund’s adjuvant (CFA) containing
0.4 mg of Mycobacterium tuberculosis (H37Ra; Difco Laboratories, Detroit, Michigan) and injected intraperitoneally with
200 ng of pertussis toxin (PT) (List Biological Laboratories
Inc., Campbell, California) on the day of immunization and 2
days later. For clinical scoring, animals were kept for at least
1 month and EAE was scored as follows: grade 1, limp tail or
isolated weakness of gait without limp tail; grade 2, partial
hind and front leg paralysis; grade 3, total hind leg paralysis;
grade 4, total hind leg and partial front leg paralysis; grade 5,
moribund or dead animal.
Antibodies, Reagents, Enzyme-Linked Immunosorbent Spot
(ELISPOT) Assay, and Enzyme-Linked Immunosorbent Assay (ELISA)
Murine CTLA4Ig was obtained from Bristol-Myers Squibb
(Seattle, Washington). Anti-ICOS-L monoclonal antibody
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(clone HK5.3)24 and anti-OX40L (clone RM 134L)25 were produced by Bioexpress Cell Culture Inc. (Kaysville, Utah) and
administered to mice intraperitoneally at 200 μg starting from
the day of the immunization and every other day until day
10 postimmunization. Control IgG antibodies were given according to the same protocol. For ELISPOT assay, 96-well nitrocellulose plates (Millipore, Bedford, Massachusetts) were
coated with 4 μg/ml purified mouse anti-interferon (IFN)-γ,
anti-interleukin (IL)-10 (all from BD Biosciences, San Diego,
California), and anti-IL-17 (ELISPOT kit; eBioscience, San
Diego, California) overnight at 4°C. After blocking with 1%
BSA, 2 to 5 × 105 cells were loaded in each well and incubated
with 0 to 100 μg/ml antigen peptide for 36 hours at 37°C.
After washing, corresponding plates were incubated with 2
μg/ml biotinylated anti-IFN-γ, anti-IL-10, or anti-IL-17 overnight at 4°C. The plates were washed, then incubated with
alkaline phosphatase (Sigma, St. Louis, Missouri) at 1:10,000
for 2 hours at room temperature, and developed in BCIP/
NBT (Sigma) solution. Spots were counted using a computer-assisted ELISPOT Image Analyzer (Cellular Technology
Limited, Cleveland, Ohio). IFN-γ (ELISA kit; R&D Systems,
Minneapolis, Minnesota) production was assessed in the culture supernatants by ELISA 2 days after ex vivo stimulation
according to the manufacturer’s protocol.
Intracellular Cytokine Staining
Cells were isolated from peripheral tissues or from the CNS
and were restimulated with phorbol 12-myristate 13-acetate
(20 ng/ml), ionomycin (300 ng/ml), and 2 mmol/L monensin (GolgiStop; BD PharMingen, San Diego, California) for
4 hours at 37°C. Cells were washed and stained for surface
markers by incubating at room temperature for 20 minutes.
After two washes in PBS containing 2% FCS and 0.1% sodium azide, the cells were treated with 1% paraformaldehyde
and fixed with buffer containing saponin according to the
manufacturer’s recommendations (BD PharMingen). Following permeabilization, the phycoerythrin (PE)-conjugated
anti-cytokine antibodies were added for 20 minutes at room
temperature, and the cells were washed and analyzed by
using a FACSCalibur Flow Cytometer (BD Biosciences, San
Jose, California). Cytokine Abs and their corresponding isotype controls from BD PharMingen, IL-4, IL-17, and IFN-γ,
were used.
Confocal Microscopy
For immunohistochemistry, animals were sacrificed and
perfused with 4% paraformaldehyde in PBS; then, brain and
spinal cord tissues were harvested and postfixed, dehydrated with 30% sucrose, placed in optimal cutting temperature,
and stored at −80°C until use. The following antibodies were
purchased from BD PharMingen: rat anti-CD4 (1:100), rabbit
anti-glial fibrillary acidic protein (GFAP) (1:100), rabbit antilectin B4 (1:100), mouse anti-SMI32 (1:100), rhodamine goat
anti-rat (1:250), fluorescein isothiocyanate (FITC) goat antirabbit (1:500), and FITC goat anti-mouse (1:500). Thirty-μmthick longitudinal sections of spinal cord tissues from mice
exhibiting EAE, and control mice were washed with PBS,
then blocked in PBS containing 8% horse serum, 3% BSA, and
0.3% Triton X-100. The sections were incubated with prima-
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ry antibodies overnight at 4°C, washed, and incubated with
the appropriate combination of secondary antibodies for 1
hour in blocking buffer. The sections were stained with the
nuclear stain, TOTO-3 (Molecular Probes, Carlsbad, California), and mounted, and images were captured using confocal
imaging and LSM510 software (Zeiss, Jena, Germany). Averaged numbers of CD4 and lectin B4-positive cells from at
least three different levels of sectioning per spinal cord (two
samples per group) were counted under X63 magnification.
T Cell Preparation, Phenotyping, and Adoptive Transfer
The memory CD4+ cell populations were characterized by
flow-cytometric analysis using rat anti-CD44-FITC, CD62LAllophycocyanin, ICOS-PE, CD28-PE, CTLA4-FITC, OX40PE, (CXC chemokine receptor 3)-PE, and appropriate isotype
antibody controls (all purchased from BD Biosciences). PE
anti-mouse CCR7 and T-bet were from eBioscience (San Diego, California). For adoptive transfer studies, splenocytes
from naïve, primed (immunized with MOG35-55 for 12 days),
and long-term immunized mice (immunized with MOG for
100 days) were pooled separately and enriched for CD4+ T
cells (negative selection) by magnetic cell separation (MACS)
(Miltenyi Biotech, Auburn, California). The CD4+ cells were
quantified, stained with rat anti-mouse CD44-FITC, and sorted using a BD FACSAria cell sorter (BD Biosciences). Finally,
1 to 1.5 × 106 sorted naïve, effector, or memory CD4+ T cells
were adoptively transferred by i.v. injection into TCRαβ-/- recipients. Mice were immunized in the flank with MOG/CFA
and injected intraperitoneally with 200 ng of pertussis toxin
on the day of immunization and 2 days later.
Activation-Induced Cell Death
Splenocytes were isolated from B6 mice immunized with
MOG35-55/CFA for 10 days (effector cells) or for more than
120 days (memory cells). After activation with MOG peptide
(0 to 25 μg/ml) in vitro for 4 days, cells were stained with
7-amino-actinomycin D (7-AAD) (BD Biosciences) and Annexin V (BD Biosciences), followed by fluorescence-activated
cell sorting (FACS) analysis, and the percentage of apoptotic
cells was quantitated.
Western Blot
The anti-Bcl-2 antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, California), and the immunoblot
technique was performed according to standard protocols.
Expression Analysis by Real-Time PCR
Total RNA was extracted from specific cell populations using the Stratagene (La Jolla, California) RNA kit and transferred directly into the RT-PCR using the Applied Biosystems Taqman kit (Applied Biosystems, Foster City, California). Samples were subjected to real-time PCR analysis on
an Applied Biosystems PRISM 7000 Sequencer Detection
System under standard conditions. Genes analyzed were detected using commercially available assays (Applied Biosystems). Relative mRNA abundance was normalized against
glyceraldehyde-3-phosphate dehydrogenase.
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MHC II IAb Tetramer Staining Based on Flow-Cytometric
Analysis
The MHC II IAb tetramer was provided by V. Kuchroo. Four
days after the activation of lymphoid cells, cell suspensions
were enriched for T cells by Ficoll-Hypaque density gradient
centrifugation. As a control for the tetramer, another group
of C57BL/6 mice was immunized for 14 or 100 days with
ovalbumin (100 μg) in CFA + PT, and splenocytes were used
for the tetramer staining. The cells from all groups were incubated with IAb multimers (30 μg/ml) in Dulbecco’s modified
Eagle’s medium supplemented with IL-2 (5 μmol/L) at 37°C
for 3 hours. The cells were then washed and stained with
anti-CD4 (CD4-Allophycocyanin) and 7-AAD (BD PharMingen). After incubating at room temperature for 20 minutes,
the cells were washed and analyzed using a FACSort (BD
Biosciences). The number of cells positive for tetramer-PE
(MOG35-55) was then determined in live (7-AAD-negative),
CD4-positive populations.
Statistical Analysis
The two-tailed Mann-Whitney and unpaired t-tests were
used to compare disease, cell proliferation, and cytokine
production. Fisher’s exact test was used to compare disease
incidence.
Results
Characterization of Autoreactive Memory CD4+ T Cells
We isolated CD4+CD44hi T cells from C57BL/6 mice after recovery from acute disease, greater than 100 days after immunization with MOG35-55 in CFA and intraperitoneal injections of PT. Effector CD4+ T cells (CD4+CD44hi) were isolated
directly from short-term MOG-immunized mice around the
peak of the clinical disease (12 days). Both memory and effector CD4+ T cells express the activation molecule CD44, but
memory T cells express significantly higher levels of CD44
compared to effector CD4+ T cells (P = 0.002 by paired t-test)
and slight down-regulation of CD62L expression (see Supplementary Figure S1A, at http://ajp.amjpathol.org). One of
the defining features of memory CD4+ T cells is their survival advantage mediated by up-regulation of anti-apoptotic
molecules.26-28 We compared the survival of memory CD4+
T cells to that of effector CD4+ T cells isolated as described
above and stimulated in vitro with MOG35-55 peptide (0, 1,
and 10 μg/ml) at equal numbers (0.5 × 106/well) for 4 days
in a 96-well plate. We found higher percentages of Annexin
V binding cells in 7-AADneg/CD4+CD44hi in effector T cells
compared to memory T cells. However, there was no difference in the 7-AADpos/CD4+CD44hi gate between the two
populations (see Supplementary Figure S1B, at http://ajp.
amjpathol.org). The ability of memory cells to resist activation-induced cell death is due, at least partially, to higher
expression of the anti-apoptotic protein Bcl-2, as shown by
Western blot, of freshly isolated memory CD4+ T cells from
long-term MOG35-55-immunized mice compared to effector
cells isolated from short-term immunized mice (see Supplementary Figure S1C, at http://ajp.amjpathol.org). Moreover, carboxyfluorescein succinimidyl ester (CFSE) label-
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ing shows that memory CD4+ T cells proliferate more than
effector CD4+ T cells in response to MOG35-55 (10 μg/ml)
stimulation as shown by quantification of CFSE dilution in
the Annexin-Vneg/7-AADneg/CD4+CD44hi gate (P < 0.05) (see
Supplementary Figure S1D, at http://ajp.amjpathol.org). Interestingly, although memory CD4+ T cells proliferated more
than effector T cells only when exposed to the higher dose
of MOG35-55 (10 μg/ml), they produced higher amounts
of IFN-γ compared to effector T cells in response to 1 and
10 μg/ml of MOG35-55 peptide (see Supplementary Figure
S1E, at http://ajp.amjpathol.org).
Memory and Effector Cells Display Differential Expression
of Survival and Costimulatory Genes
To eliminate the possibility of contamination of the memory cell pool by effector cells from the antigen depot site,
we “parked” the cells in naïve syngeneic animals. CD4+ T
cells were isolated from spleens of MOG-TCR transgenic
mice (2D2) immunized with MOG35-55/CFA 14 days earlier and parked in naïve B6 recipients for 100 days to generate memory T cells. CD4+ Vβ11+ Vα3.2+ T cells were sorted
from the spleens of recipient mice with a recovery rate of 8
to 12 × 103 cells per recipient. Using quantitative RT-PCR,
we found a higher level of the antiapoptotic molecule Bcl-2
(2.3-fold higher) and a lower level of the pro-apoptotic tumor
necrosis factor receptor p55 (3.6-fold) and caspase-8 (2.4-fold) in
the memory T cell population compared to effector CD4+ T
cells. There was no difference in the mRNA expression of
Bcl-xL (see Supplementary Figure S2A, at http://ajp.amjpathol.org). We then compared the mRNA expression of
the costimulatory molecules CD28, ICOS, and OX40 in addition to CTLA4. In comparison to memory T cells, effector
T cells expressed 2.5-and 2.8-fold higher levels of CD28 and
CTLA4 mRNA, respectively. In contrast, ICOS expression
was higher in the memory T cell population (3.3-fold), suggesting different requirements for costimulation between
the two populations. There was no significant difference in
OX40 expression (see Supplementary Figure S2B, at http://
ajp.amjpathol.org). Finally, we quantified the transcripts of
chemokine receptors on MOG-specific effector and memory
CD4+ T cells. We found that CXCR3 transcripts were at their
highest level only in memory T cells (12.4-fold) compared to
effector T cells. Similarly, higher levels of CCR5 were also
detected on the memory T cell population (2.3-fold) compared to effector T cells. No significant differences in the levels of CXCR4 and CCR7 between the two populations were
detected (see Supplementary Figure S2C, at http://ajp.amjpathol.org). Since CCR7 is an important receptor for central
memory cell homing, we compared the protein levels of this
chemokine receptor between memory subpopulations (TCM
and TEM) and effector cells. FACS analysis showed that although TCM (CD4+CD44hiCD62Lhi) cells express higher levels
of CCR7 as compared to short-term activated T cells (MFI:
785 ± 89.2 versus 456.5 ± 18.7; P < 0.05), there was no significant difference in CCR7 protein expression between TEM
(CD4+CD44hiCD62Llo) and activated effector T cells (MFI:
479.3 ± 25.3 versus 456.5 ± 18.7).
Next, we measured the relative mRNA expression of the
transcription factors T-box 21, RORγt, and GATA3. Interestingly, the T-box 21 message was very prominent in the mem-
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ory T cell population (∼15-fold increase) (see Supplementary
Figure S2D, at http://ajp.amjpathol.org). We also measured
the frequency of T-bet-positive cells by intracellular staining.
The number of T-bet-positive cells was higher in the memory
cell population compared to the effector T cells (22.3 ± 5.1
versus 12.6 ± 3.9, P <0.01), although their mean fluorescence
intensity levels were identical (data not shown).
Memory CD4+ T Cells Induce More SevereDisease Than Effector Cells
CD4+CD44hi memory T cells from long-term (100 days)
immunized WT mice were sorted and transferred into lymphopenic TCRαβ-/- mice by i.v. injection. Effector CD4+CD44hi
and naïve CD4+CD62L+ cells isolated fromimmunized (12
days) and non-immunized WT mice, respectively, were used
as controls. Following cell transfer, recipients were immunized with MOG35-55/CFA + PTand observed for EAE development. Although EAE onset was similar between recipients of memory and effector cells, disease was significantly
more severe in memoryCD4+ cell-induced disease compared
to that induced by effector T cells (mean maximal score 3.0 ±
0.2 versus 2.2 ± 0.2, P = 0.006 by Mann-Whitney test). As expected, adoptive transfer of naïve T cells caused a mild and
delayed EAE compared to disease induced by memory cells
(mean maximal score 3.0 ± 0.2 versus 0.8 ± 0.4, P < 0.0001
by Mann-Whitney test) (Figure 1A; Table 1). The enhanced
disease severity was not due to unequal frequency of MOGspecific cells at the time of transfer, since the precursor frequency of IAb-MOG35-55tetramer. cells was actually in favor
of the effector cell population (Figure 1B).
To analyze the peripheral immune responses of the transferred cells, we isolated draining lymph nodes and splenocytes from TCRαβ-/- mice recipients of memory or effector
CD4+ T cells 12 days after immunization. Cells from the
memory T cell recipient group exhibited more proliferation
than those from the effector T cell recipients after culture
with 10 and 100 μg of MOG peptide in vitro (P < 0.001 and
P < 0.01, respectively) (Figure 1C). The cytokine production
of freshly isolated memory or effector cells showed that the
frequency of IFN-γ-producing cells by intracellular staining
was significantly higher in the memory cell population (15.6
± 2.9 versus 7.6 ± 4.6, P < 0.05). We also observed that memory T cells produced slightly more IL-17 than effector cells
(2.6 ± 0.9 compared to 1.1 ± 0.6) (Figure 1D). There was no
difference in the frequency of cells producing IL-4 between
the two groups (Figure 1D).
The heightened response in the memory recipients was
not due to unequal homeostatic proliferation of the memory
and effector T cells. We adoptively transferred CFSE-labeled
MOG-specific effector or memory CD4+ T lymphocytes into
naïve TCRαβ-/- mice. Three, 6 and 10 days after adoptive
transfer, spleen cells were isolated and the percentage of cells
that underwent proliferation was calculated based on the
CFSE dilutions as percentage of CFSEdim cells of alive CD4.
cells (7-AADneg/Annexin-Vneg). We found that effector T cells
expanded more than memory T cells at 3 and 6 days after
transfer, but by day 10 the expansion was similar (see Supplementary Figure S3, at http://ajp.amjpathol.org). These data
exclude a possible role of homeostatic mechanisms increasing the pool of memory T cells in the lymphopenic hosts.
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Figure 1. Adoptive transfer studies into TCRαβ-/- mice. A: A representative experiment showing transfer of disease in TCRαβ-/- mice. Spleens and lymph nodes from
wild-type mice were harvested at 12 days (Effector‚ Δ) or more than 100 days (Memory, ■) postimmunization; CD4+ MACS were negative-selected and cell-sorted
for expression of CD44. Naïve CD4+ T cells were isolated from nonimmunized mice and used as control. The cells were resuspended in PBS at a concentration of 1 ×
106/100 μl and injected i.v. into TCRαβ-/- mice. Recipients were immunized with MOG35-55 peptide on the day of transfer and graded for disease daily. The mean
daily disease grade ± SEM for each group (n = 8 to 16 mice per group) is shown. B: Frequency of MOG-specific CD4+ T cells. Splenocytes isolated from short- or
long-term MOG-immunized WT mice (n = 3 to 5) were activated in vitro, and the cell suspensions were enriched for T cells by Ficoll-Hypaque density gradient centrifugation and incubated with IAb multimers (30 μg/ml) in Dulbecco’s modified Eagle’s medium supplemented with IL-2 (5 μmol/L) at 37°C for 3 hours. The cells
were acquired using a FACSort, and the number of tetramer-PE (MOG35-55)-positive cells was then determined in live (7-AAD-negative) CD4-positive populations.
Splenocytes from B6 mice immunized for 10 (effector) or 100 (memory) days with ovalbumin (Ova) were stained with MOG35-55 tetramer and used as control, confirming the specificity of the tetramer (representative of three independent experiments). C: Splenocytes from mice that received effector or memory T cells were cultured with MOG35-55 peptide at 1, 10, and 100 μg/ml and cell proliferation was measured by [3H]thymidine incorporation. The proliferation rate was significantly
higher in cultures from the memory () T cell group compared to the effector () group. D: Intracellular FACS staining of splenocytes from MOG35-55-immunized
B6 mice. Spleen cells were isolated and activated in vitro with anti-TCR and anti-CD28 antibody for 6 hours and stained with anti-CD4-peridinin-chlorophyll-protein
complex, anti-CD44-FITC, and a variety of cytokine-PE antibodies. **P < 0.001; ***P < 0.0001.

Another possible confounding factor could be unequal
expansion of CD4+CD25+ regulatory T cells after in vivo
transfer of the effector versus memory T cells. At the time
of transfer, the percentage of CD4+CD25+Foxp3+ cells was
comparable between the memory and the effector populations (8.3 ± 0.7 versus 7.5 ± 0.6, P = 0.5) (data not shown). To
explore the possibility of unequal expansion of regulatory T
cell populations in vivo after immunization, splenocytes isolated from recipients of either effector or memory CD4+ cells
were isolated 10 days after immunization, and the percentage of CD4+CD25+Foxp3 was measured. We found that the
percentage of regulatory T cells was similar in TCRαβ-/- mice
that received memory or effector CD4+ cells (9.7 ± 1.4 from
the effector T cell recipients compared to 11.2 ± 0.1 in the
memory T cell recipients, P = 0.4) (data not shown).
In Vivo Dynamics of MOG-Specific Memory and Effector
CD4+ T Cells
To study the disease dynamics induced by the transfer of

antigen-specific memory CD4+ T cells, we generated two
lines of 2D2 mice (MOG-TCR transgenic) that express Thy1.2
or the Thy1.1 congenic markers. First, we showed that the
transfer of memory T cells from 2D2 mice into TCRαβ-/- mice
induced more severe disease than did their effector counterparts (mean maximal score 3.8 ± 0.4 versus 2.8 ± 0.1, P =
0.004 by Mann-Whitney test) (Figure 2A). Second, we studied the expansion, phenotype, and trafficking of autoreactive memory and effector CD4+ T cells by transferring both
cell types into one WT hybrid recipient. Using MOG TCRtransgenic mice that express Thy1.2 or the Thy1.1 congenic
markers, we tracked the Thy1.1 (memory) and Thy1.2 (effector) CD4+ T cells in the periphery before and during disease
onset, and in the CNS compartment during the peak of the
disease. To do this, equal numbers of MOG TCR transgenic
Thy1.1 memory and Thy1.2 effector CD4+CD44hi T cells were
transferred i.v. into Thy1.1/Thy1.2 hybrid hosts and challenged with MOG35-55 peptide. At the time of transfer, there
were phenotypic differences between memory and effector
cell populations: as measured by flow cytometry, ICOS and
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Table 1. Induction of Disease by Transfer of WT Memory, Effector, or Naïve CD4+ T Cells in TCRαβ-/- Mice
Group 		
Incidence 		
Mean day of onset ± SEM 		
Mean maximum score ± SEM 		
Death
Memory CD4+
16/16 		
12.0 ± 0.4 				
3.0 ± 0.2* 				
2/16
+
Naive CD4
4/8 		
16.0 ± 0.9 				
0.8 ± 0.4** 				
0/8
Effector CD4+
16/16 		
13.5 ± 0.6 				
2.2 ± 0.2 				
0/16
TCRαβ-/- mice received naïve, effector, or memory CD4+ T cells on day 0 and were immunized on the same day with MOG35-55 peptide emulsified in CFA and
monitored for the development of EAE. Statistical analysis was performed using the Mann-Whitney test.
*P = 0.006; **P < 0.0001

CXCR3 protein levels were significantly higher in the memory T cells, whereas CTLA4 and CD28 protein expression was
lower in the memory T cells compared to effector cells (Figure 2B), consistent with the mRNA data. The expression of
OX40 was comparable between memory and effector T cells
(Figure 2B).
We calculated the frequency of IFN-γ- and IL-17-producing
cells at different time points. In the periphery (spleen and
lymph node tissues), the frequency of IFN-γ-producing cells
was higher in memory cells compared to effector cells on day
8 (14.3% ± 1.4 versus 3.4% ± 0.5; P < 0.01), but the percentage
of IL-17-producing memory cells was lower than that of effector cells (6.6% ± 0.3 versus 12.9% ± 1.3; P < 0.05) (Figure
2C). Similarly, on day 14 (disease onset), the frequency of
IFN-γ-producing cells remained higher in memory cells than
effector cells (25.4% ± 2.3 versus 7.5% ± 1.2; P < 0.01) and the
IL-17-producing cells lower than in the effector cell population (3.2% ± 1.9 versus 16.1% ± 2.3; P < 0.01) (Figure 2C). In
the CNS compartment (meningeal and spinal cord tissues),
there were few cells on day 8, but by day 14 the frequency of
IFN-γ-producing cells was higher in the memory population
(32.4% ± 2.1 versus 15.7% ± 1.7; P < 0.05) and there was no
difference in the frequency of IL-17-producing cells (Figure
2C). Further analysis indicated similar frequencies of IL-4-,
IL-5-, and IL-10-expressing cells between the two populations during all stages of the disease (data not shown). More
importantly, at the very late stage of the disease (day 60),
there was an exclusive infiltration of memory cells in the
CNS (over 90% of transferred cells) of which 30.4% ± 6 were
producing IFN-γ and 11.9% ± 3.5 were producing IL-17.
We calculated the relative frequency of transferred memory
and effector T cells in the CNS compartment before, during,
and after disease onset. During the presymptomatic disease
phase (day 8), 59.3% ± 6.1 of the transferred cells were effector cells in the meninges, and no infiltrates were present in
the target organ. However, at the peak of disease (day 14),
the memory cells constituted 77.6% ± 6.6 of the transferred
T cells in the CNS compartment (P < 0.005 compared to effector cells). The memory T cells predominated also during
the late stage of the disease (day 60) (89.6% ± 7.6) in the CNS
compartment (P < 0.001).
In another set of experiments, we explored the phenotype
and migration of memory 2D2 Thy1.1 cells compared to
naïve 2D2 Thy1.2 cells activated in vivo. Therefore, MOGspecific memory (Thy1.1) and naïve (Thy1.2) were transferred into hybrid hosts and challenged with MOG35-55
peptide. The FACS analysis indicated that the distribution
of IFN-γ-producing cells was similar to our previous experiments, with a higher frequency of IFN-γ-producing cells in
the memory cell population in the periphery and in the CNS
(Figure 2D). Unlike what we observed in the effector versus
memory transfer, there was a slight increase in the frequency
of memory IL-17-producing cells in the CNS (Figure 2D).

Increased CNS Infiltration of Memory CD4+ T Cell-Mediated
Inflammation during Eae
Histological examination of the CNS of TCRαβ-/- mice sacrificed on day 12 and day 32 (Figure 3 and Table 2) postimmunization revealed significantly more T cell infiltrates in CD4.
memory T cell recipients (Figure 3A and Table 2) compared
to CD4+ effector T cell recipients (Figure 3D and Table 2), and
more microglia activation (Figure 3B versus 3E and Table 2).
It should be noted that, unlike effector cell infiltration in the
CNS, memory CD4+ T cell infiltrates and microglia activation were detected in the CNS through the late stages of the
disease (day 32) (Figure 3 and Table 2). To analyze whether disease transfer affects axonal integrity, we used SMI32
monoclonal antibody, which reacts with a nonphosphorylated epitope in neurofilament H in demyelinating axons, as
a marker of axonal damage.29 We also used GFAP antibody,
a marker of astrocytes that is induced during astrocytic activation.30 Our data showed that memory CD4+ T cells were
associated with greater astrocytic activation (Figure 3H) and
axonal damage (Figure 3N), as demonstrated by increased
fluorescence staining of GFAP and SMI32, respectively, compared to recipients of effector cells (Figure 3, K and Q). A
potential explanation for the increase in CNS infiltration in
recipients of memory CD4+ T cells may be that memory T
cells migrate to the CNS more efficiently. This is in agreement with our present data of the mRNA and protein levels of the chemokine receptor expression on MOG-specific
memory CD4+ T cells demonstrating that these cells express
higher levels of CXCR3 and CCR5 compared to effector CD4+
T cells, indicating that the severe disease induced by memory T cells is related, at least partially, to increased migration
of these cells to the CNS.29
Costimulatory Requirements of Memory Versus Effector
CD4+ T Cells in Vivo
Our group and others have shown previously that CD28-B7
blockade by CTLA4Ig protects animals from actively induced
EAE.31,32 As shown above, CD28 expression is higher in MOG
TCR-specific effector T cells as compared to the memory T
cell population (Figure 2; see Supplementary Figure S2, at
http://ajp.amjpathol.org). To investigate the costimulatory
requirements of memory and effector CD4+ T cells in vivo,
TCRαβ-/- recipient mice that received either memory or effector CD4+ cells were treated with CTLA4Ig (200 μg) every
2 days from day 0 through day 10 after immunization. The
control group received control Ig. Our data demonstrated
that although CTLA4Ig administration dramatically suppressed the disease induced by transferring effector cells
(mean maximal score 0.4 ± 0.1 versus 2 ± 0.2, P < 0.001; incidence 25% versus 100%, P < 0.001), there was only a slight
decrease in the induction of clinical disease in the group of

Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune Encephalomyelitis

		

417

Figure 2. Competitive assay of MOG-specific memory, effector, and naïve activated CD4+ T cells. A: A
total of 1 × 106 MOG-TCR transgenic effector CD4+
(CD4+CD44hi, from day 10 postimmunization, Δ‚) or
1 × 106 memory CD4+ (CD4+CD44hi, from day 100
postimmunization, ■) were transferred into TCRαβ-/mice (n = 6 to 8) that were immunized with MOG3555. Disease induced by MOG-TCR transgenic memory CD4+ cells was more severe than that induced by
effector CD4+ cells (mean maximal score 3.8 ± 0.4 versus 2.8 ± 0.1, P = 0.004), although the time to onset was
similar in the two groups. B: Phenotypic characterization of MOG TCR-specific memory, effector, and
naïve CD4+ T cells. Cells were stained for different
markers and analyzed by flow cytometry. Results are
expressed as MFI. C: Time course- and tissue-specific
analysis of cytokine profile of autoreactive memory
(Thy1.1) and effector (Thy1.2) CD4+ T cells that were
transferred into Thy1.1/Thy1.2 hybrid recipients. D:
Another set of experiments was performed to compare memory (Thy1.1) to naïve-activated (Thy1.2) T
cells in other hybrid recipients. Cells were collected
from the peripheral organs (spleens and lymph
nodes) and from the CNS compartment (meninges
and spinal cords) and analyzed by flow cytometry
before EAE onset (Presymptomatic) and at the peak
of the disease (Onset) in the periphery and the CNS.
Data represent the percentage of cytokine-positive
cells and the mean fluorescence intensity of the surface molecule expression. Bars represent SEM values.
*P < 0.05; **P < 0.001.

mice that received memory cells (mean maximal grade 2 ±
0.2 compared to 2.5 ± 0.1, P = 0.03) (Figure 4A), and overall
disease incidence was similar to the control group (100%).
We investigated the cytokine profile in treated mice. Spleen
and lymph node cells were isolated from treated mice 12
days after immunization and exposed to MOG peptide (50
μg/ml), and the cytokine profile was characterized. The effects of in vivo CTLA4Ig administration on the frequency of
IFN-γ-producing cells were evident in mice that received effector cells (P < 0.01) and to a lesser extent in the mice that
received memory cells (P < 0.05) (Figure 4B). Interestingly,
CTLA4Ig administration increased IL-10 production and inhibited IL-17 production in cells isolated from the effector T
cell recipients (P < 0.05 compared to control Ig-treated mice),
whereas no such effects were seen in the memory T cell recipients (Figure 4B).
Next, TCRαβ-/- mice that received either memory or effector
CD4+ cells were treated i.p. with anti-B7h (ICOS-L) (200 μg)
every second day from day 0 through day 10 after immunization. Although anti-B7h antibody treatment worsened the
disease induced by transferring effector cells (mean maximal
grade 2 ± 0.2 versus 2.6 ± 0.1, P < 0.05), it provided significant protection in mice that received memory cells (mean
maximal grade 2.9 ± 0.1 versus 1.8 ± 0.1, P < 0.005) (Figure
4C). In vitro, the cytokine profile of lymphoid cells isolated
12 days after immunization resembled in vivo disease, with
decreased frequency of IFN-γ-producing cells (P < 0.05) in
the memory cell recipients treated with anti-B7h compared
to control Ig mice. There was no such decrease in effector
cell recipients treated similarly (Figure 4D). Furthermore,
lymphoid cells from memory T cell recipients produced
significantly less IL-17 and more IL-10 after treatment with
anti-B7h (P < 0.05 compared to control mice), whereas IL-17

production by the effector T cell recipients treated with antiB7h was similar to that of recipients treated with control Ig
(Figure 4D).
We tested the effect of OX40L-OX40 blockade in this model
using a blocking antibody against OX40L. TCRαβ-/- mice received either memory or effector CD4+ T cells in the presence
of anti-OX40L (200 μg) every second day from day 0 through
day 10 after immunization. Surprisingly, antibody treatment
ameliorated disease in recipients of memory (mean maximal
grade 2.9 ± 0.1 vs. 1.7 ± 0.4, P < 0.01) and effector CD4+ T
cells (mean maximal grade 2 ± 0.2 versus 1.2 ± 0.2, P < 0.05)
(Figure 4E). The frequency of IFN-γ-producing cells was
decreased in the anti-OX40L-treated memory cell recipients
(P < 0.05) as well as the effector cell recipients treated similarly (P < 0.01) (Figure 4F). The amelioration of the clinical
score induced by OX40-OX-40L pathway blockade was associated with enhanced IL-10 production and reduction of
IFN-γ-producing lymphoid cells of memory and effector T
cell recipients, whereas IL-17 production was not affected
(Figure 4F).
Discussion
The success of experimental immunomodulatory and tolerance strategies has been largely restricted to naïve hosts
that do not harbor significant numbers of memory T cells;
for example, mice housed in a pathogen-free environment.
These strategies induce immunological tolerance to a foreign
antigen by exploiting the same principles that underlie tolerance to self-antigens: deletion, anergy, regulation, and immune deviation. Therefore, for such strategies to work in immunologically experienced hosts, such as humans, relevant
experimental models must first be developed to address
whether memory T cells can be “tolerized” in vivo. The role
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Table 2. Quantification of CNS-Infiltrating T Cells in Recipients of Memory or
Effector T Cells by Immunohistology
						 Memory 			 Effector
						 group 				 group 				 Comparison
Day 12
CD4+ T cells 		 68.8 ± 13.8 			 43.5 ± 7.7 			 P < 0.05
Lectin B4+ cells
34.5 ± 7.9 			 27.8 ± 14.9 			 P = 0.45
Day 32
CD4+ T cells 		 107 ± 21 			 22 ± 4 				 P < 0.005
Lectin B4+ cells
76 ± 12 				 21 ± 6 				 P < 0.005
TCRαβ-/- mice received effector or memory CD4+ T cells on day 0 and were
immunized on the same day with MOG35-55. Spinal cords from each group
of animals were collected on day 12 and day 32 postimmunization, processed
for frozen sectioning, and immunostained for CD4 and lectin B4. Statistical
analysis was performed using an unpaired t-test. P values < 0.05 were considered significant.

Figure 3. Inflammatory cell infiltrates in the CNS of TCRαβ-/- mice recipients
of memory versus effector CD4+ T cells. Spinal cord tissues from the recipients
of memory CD4+ T cells (A-C, G-I, and M-O) or effector CD4+ T cells (D-F,
J-L, and P-R) were harvested 32 days postimmunization, processed for frozen
sectioning, and immunostained with rat anti-CD4 (A, D, G, J, M, and P; red),
anti-lectin B4 (B and E; green), anti-GFAP (H and K; green), and mouse antiSMI32 (N and Q; green). Sections were co-stained with the nuclear dye TOPO3
(blue). Merged pictures (C, F, I, L, O, and R) are shown of images captured
using confocal imaging at ×63 magnification.

of heterologous memory cells has been recognized as a barrier to transplantation tolerance.33 It is becoming clear that
results from current experimental models of autoimmune
disease may not predict outcomes in human studies; thus,
it is critical to develop animal models that address the role
of memory T cells in response to therapeutic strategies.<b.
To address this issue, we developed a new disease model of
memory CD4+ T cell-induced EAE. We validated this model
using both wild-type and MOG TCR-specific cells to avoid
any bias related to the high precursor frequency of transgenic cells.34 We showed that memory CD4+ T cells induced
more severe EAE than did their effector or naïve counterparts. The disease induced by memory cells was associated
with increased cell proliferation, Th1 cytokine production,
and more severe CNS infiltration and axonal damage. The

abundance of memory T cells in the target organ occurred
under non-lymphopenic conditions, suggesting that this persistence was not due to homeostatic proliferation-mediated
accumulation of memory T cells. Moreover, in comparison to
effector T cells, we demonstrated that memory T cells were
less susceptible to activation-induced cell death and exhibited higher expression of the anti-apoptotic Bcl-2, whereas
effector cells expressed higher levels of the death receptor
tumor necrosis factor receptor p55 and caspase-8, which are
known to interact physically to induce the pro-apoptotic protease cascade.35 Although the frequency of long-term memory MOG-specific T cells was lower than that of short-term
effector cells, the higher proliferative capacity of memory
cells could be linked to a lower susceptibility to AICD. Interestingly, we also showed that memory CD4+ T cells have
increased expression in the Th1-associated chemokine receptor, CXCR3, and increased IFN-γ production compared to
effector CD4+ T cells. A recent report showed that CXCR3
is required for recruitment of CD62L and CCR7-negative
memory T cells to reactive lymph nodes of adjuvant inoculation.36 Thus, the memory T cells that we isolated from peripheral lymphoid organs of immunized mice are heterogeneous in the expression of these homing receptors since they
are a mixture of TCM and TEM. Memory CD4+ T cells infiltrated
more than effector T cells and persisted until the late stage of
the disease. These data are consistent with previous reports
showing that CXCR3 is expressed on memory CD4+ T cells
and preferentially on activated Th1 cells37 and that a smallmolecule compound targeting CXCR3 prevents acute and
chronic allograft rejection in murine cardiac and islet transplant models.38 Other reports demonstrated that the role of
CXCR3 is not limited to T cell migration and could play an
important role in the differentiation of memory CD4+ T cells
during inflammation in humans.39,40 In contrast to the implication of CXCR3 in migration, it recently was demonstrated
that CXCR3-/- mice exhibit exaggerated severity of EAE compared with wild-type (CXCR3+/+) littermate mice.39 There
were neither quantitative nor qualitative differences in CNSinfiltrating leukocytes between CXCR3+/+ and CXCR3-/- mice
with EAE.41 Although the discrepancies between the findings
of the two groups highlight the need for further study, the
expression of this chemokine receptor at high levels in memory CD4+ T cells suggests an important role in memory T cell
migration and perhaps in memory T cell differentiation.
For the first time we compare the in vivo behavior of memory and effector T cells in the same recipient. We also show
that in addition to the production of IFN-γ, memory CD4+
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Figure 4. Differential role of costimulatory molecules in disease induced by CD4+ memory and effector T cells. A: Effects of CTLA4Ig on the clinical disease induced
by the transfer of effector or memory cells into TCRαβ-/-. B: ELISPOT data of the frequency of IFN-γ-, IL-10-, and IL-17-producing cells. Spleen cells were exposed
to MOG peptide (50 μg/ml) for 48 hours and positive cells were quantified. C: Effects of anti-ICOS-L on the clinical disease induced by effector or memory cells. D:
ELISPOT analysis of the frequency of cells producing IFN-γ, IL-10, and IL-17 was performed using spleen cells isolated from mice recipients of memory or effector
T cell. E: Blockade of OX40 costimulatory pathway using anti-OX40L monoclonal antibody in EAE induced by the memory or effector T cells. F: ELISPOT data of
the cytokine profile of memory and effector CD4+ T cells exposed to anti-OX40L or control IgG during EAE. Representative of two separate experiments (n = 8 mice
per group). *P < 0.05; **P < 0.01.

T cells produced IL-17, although this production was lower
than that of effector cells. IL-17 expression has been linked to
autoimmune diseases, although its regulation and function
are still unclear.42,43 Two recent studies showed evidence that
IL-17-producing effector CD4. T cells develop via a lineage
distinct from the Th1 and 2 lineages.44,45 This process is negatively regulated by T helper type 1 and type 2 cytokines.45
Interestingly, we observed reduced production of IL-17 associated with increased secretion of IFN-γ by memory T cells
compared to their effector counterparts during EAE. This
suggests that IFN-γ may down-regulate IL-17 in the memory
population. One of the approaches to targeting autoimmune
disease mediated by memory T cells is to block activation
pathways unique to the recall of memory T cells. There is
extensive evidence in vitro that human memory T cells do
not require CD28 costimulation for full activation.19,20,46,47 On
the other hand, there are no in vivo studies of the effect of
CTLA4Ig on memory function in an autoimmune disease
model. Recently, two reports about CD28-mediated costimulation in viral models of CD4+ and CD8+ memory T cells
demonstrated that the CD28 costimulatory pathway blockade suppressed memory T cell activation.21,22 Previously, we
and others showed the effectiveness of the costimulatory
signal blocker CTLA4Ig in EAE,31,48-50 but we hypothesized
that CTLA4Ig would not be sufficient to induce tolerance of
memory T cells.51,52 A clinical trial of CTLA4Ig in MS is currently under way (S.J. Khoury and colleagues), so it is critical
to understand the limitations of such an approach in treating
human disease. In this report, we showed that the numbers
of CD28 and CTLA4 transcripts were lower in MOG-specific
memory T cells compared to effector and naïve T cells. Furthermore, blocking CD28-B7 costimulation with CTLA4Ig

caused weak protection of EAE induced by memory cells and
did not suppress the production of pro-inflammatory cytokines IFN-γ and IL-17, in contrast to the effective suppression
of effector cell-induced disease that we usually obtain with
the same regimen of CTLA4Ig.
Recent studies identified a novel costimulatory pathway involved in the activation of antigen-experienced but not naïve
T cells.17 The pathway is activated by the interaction of ICOS
on T cells with B7h (B7RP-1) on antigen-presenting cells.53
Costimulation through ICOS is crucial for the activation of
previously primed T cell populations, which include memory
T cells. Blocking this pathway in EAE during the efferent immune response (9 to 20 days after immunization) abrogated
disease, whereas blockade during antigen priming (1 to 10
days after immunization) exacerbated disease.54 Our model
has the advantage of unequivocally showing the differential effect of ICOS blockade on effector versus memory cells.
Our present findings also demonstrate that the decrease in
expression of mRNA and protein level of ICOS has functional relevance. It is noteworthy that Park et al.45 have shown
that the ICOS-B7h pathway is required for the production
of IL-17 in murine T cells. These data are consistent with our
present findings that blockade of B7h was beneficial when
EAE was induced by transfer of CD4+ memory cells and was
associated with a decrease in IL-17 production, whereas it
worsened the disease when induced by transfer of CD4+ effector cells. It is also striking that ICOS mRNA is expressed
at a significantly higher level on memory T cells compared
to effector cells, which is consistent with an important role
of the ICOS-B7h pathway in memory T cell-induced EAE.
It is commonly stated that activation of memory T cells is
independent of costimulatory signals; however, our in vivo

420 Elyaman, Kivisäkk, Reddy, Chitnis, Raddassi, Imitola, Bradshaw, Kuchroo, Yagita, Sayegh & Khoury

studies demonstrate that memory T cells are sensitive to costimulatory blockade but have different requirements from
effector T cells.
The OX40-OX40L pathway appears to regulate multiple
aspects of the T cell response. OX40 costimulation on effector T cells promotes cell survival, proliferation, and effector
differentiation.55 Also, OX40 costimulation prevents T cell
anergy and allows anergic T cells to acquire potent effector
functions.56 Furthermore, OX40 is instrumental in the generation of the memory recall response. Studies using OX40deficient mice clearly showed that the most profound impact
of OX40 deficiency on the immune response is the impaired
generation of memory T cells.57,58 Recently, in a mouse model
of skin transplantation, memory T cells generated by homeostatic proliferation and resistant to CD28/CD154 blockade in
transplant rejection are sensitive to OX40 blockade.59 This is
in agreement with our present findings in which anti-OX40L
therapy ameliorated EAE mediated by memory T cells and
reduced IFN-γ-producing cells.
In our model, the percentage of CD4+CD25+Foxp3+ cells
in the transferred population was comparable between the
effector and memory populations. After immunization, the
percentages of these CD4+CD25+Foxp3+ cells remained similar in the two groups. These data underscore that differential
expansion of regulatory T cells is not the cause of disparity
in disease severity between the effector and memory T cell
recipients. Our findings also suggest that regulatory T cells
may have less ability to control memory than effector T cells
in vivo.
In conclusion, we provide a clinically relevant novel model
of autoimmune disease mediated by memory T cells that is
useful for the study of disease pathogenicity as well as for
the investigation of immunological tolerance strategies.
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